RESUMEN
New lines of treatment targeting cytokines have been successfully developed recently and are now widely used in therapy. They are based on passive administration of cytokine inhibitors either soluble receptors or mAbs and the major example is TNFalpha in rheumatoid arthritis (RA). Since a few years, our group has developed a novel alternative approach targeting cytokines by using active immunization against biologically inactive but immunogenic cytokine derivatives. In the present work, we present a new aspect of this research, based on immunization against specific cytokine peptides chosen by molecular modelling. We could elicit a significant humoral response against four TNFalpha peptides by active immunization, and show that the Abs generated cross-reacted with the native cytokine with good titers as determined by ELISA. Interestingly, during coimmunization experiments with couples of peptides, one showed a clear immunodominant effect over the other. Overall, we could not show the neutralization of TNFalpha biological activity in vitro by the immunized sera, but it seems that it is not a prerequisite to observe clinical efficacy. Indeed, using the LPS/galactosamine-induced shock, we could demonstrate that one of the four peptides tested conferred a clinical protection. These results validate the feasibility and efficacy of active immunization against cytokine peptides, and confirm that active immunization against cytokines could represent in the future an alternative to passive immunization in many diseases.
Asunto(s)
Anticuerpos Bloqueadores/biosíntesis , Factor de Necrosis Tumoral alfa/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Bloqueadores/análisis , Formación de Anticuerpos/inmunología , Especificidad de Anticuerpos , Reacciones Cruzadas , Diseño de Fármacos , Femenino , Galactosamina/toxicidad , Lipopolisacáridos/farmacología , Ratones , Modelos Moleculares , Datos de Secuencia Molecular , Pruebas de Neutralización , Fragmentos de Péptidos/inmunología , Choque/inducido químicamente , Choque/prevención & control , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
Cancer cells may escape immune surveillance by secreting in their microenvironment soluble factors that may locally paralyze the stromal effector immune cells. In the human uterine cervix cancer, HPV-16 E7 protein, released in the stroma, should contribute to cancer cells immune escape since this protein inhibits the cellular immune response to recall antigens or alloantigens and strongly enhances the release of immunosuppressive cytokines by APCs. This prompted us to prepare a therapeutic vaccine triggering anti-E7 neutralizing Abs to antagonize the E7-induced stromal immunosuppressive effects and allow cellular immune reaction towards cancer cells including specific CTLs, induced by conventional vaccine, to be effective. Since HPV-16 is a mucosotropic virus, this therapeutic vaccine has been prepared to generate systemic as well as mucosal immunity.
Asunto(s)
Vacunas contra el Cáncer/inmunología , Carcinoma/terapia , Tolerancia Inmunológica/inmunología , Proteínas Oncogénicas Virales/inmunología , Células del Estroma/inmunología , Neoplasias del Cuello Uterino/terapia , Animales , Carcinoma/inmunología , Cuello del Útero/citología , Cuello del Útero/inmunología , Femenino , Humanos , Ratones , Papillomaviridae/inmunología , Proteínas E7 de Papillomavirus , Toxoides/inmunología , Neoplasias del Cuello Uterino/inmunologíaRESUMEN
Anti-Tat vaccination experiments were carried out in mice with a view to inducing systemic in addition to mucosal immunity. For this, three types of immunizing preparations were tested, which consisted of Tat toxoid embedded in either an adjuvant oily structure (IMS), or nanoparticles of chitosan, or microparticles of polylactide-co-glycolide (PLG). Administered by either the intranasal or oral route all preparations triggered anti-Tat IgG and IgA antibodies. Sera from mice immunized with either of these preparations could also inhibit significantly the Tat transactivating activity. These results open up a new avenue to the development of an effective anti-AIDS protective vaccine.